🇪🇺 Movantik in European Union

EMA authorised Movantik on 25 September 2014

Marketing authorisations

EMA — authorised 25 September 2014

  • Status: approved

EMA — authorised 7 December 2014

  • Application: EMEA/H/C/002810
  • Marketing authorisation holder: Grunenthal GmbH
  • Local brand name: Moventig
  • Indication: Treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).
  • Status: approved

Read official source →

Movantik in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in European Union

Frequently asked questions

Is Movantik approved in European Union?

Yes. EMA authorised it on 25 September 2014; EMA authorised it on 7 December 2014.

Who is the marketing authorisation holder for Movantik in European Union?

Averitas is the originator. The local marketing authorisation holder may differ — check the official source linked above.